ORMP Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
2.8M
-24.4%
3.7M
-35.5%
5.7M
+133.7%
2.4M
-2.5%
2.5M
R&D
0
-100.0%
1.6M
-19.8%
2.0M
+72.4%
1.2M
+11.5%
1.0M
SG&A
2.8M
+33.9%
2.1M
-43.9%
3.7M
+189.2%
1.3M
-12.4%
1.5M
Operating Income
-2766000
+24.4%
-3659000
+35.5%
-5672000
-133.7%
-2427000
+2.5%
-2489000
EBITDA
-2735000
+24.6%
-3629000
+35.7%
-5642000
-135.5%
-2396000
+2.6%
-2459000
Net Income
78.2M
+104.0%
38.3M
+282.8%
10.0M
-79.3%
48.4M
+264.9%
13.3M
EPS (Basic)
$1.90
+102.1%
$0.94
+308.7%
$0.23
-80.2%
$1.16
+262.5%
$0.32
EPS (Diluted)
$1.84
+102.2%
$0.91
+333.3%
$0.21
-81.4%
$1.13
+264.5%
$0.31
Shares (Diluted)
42.5M
+1.3%
42.0M
-2.5%
43.1M
+0.7%
42.8M
+0.4%
42.6M
Oramed Pharmaceuticals (ORMP) โ€” Financials